Afamelanotide News

← Back to News Overview

---

Afamelanotide currently has 0 news articles, with 20 predicted indications.

This page combines the AI-predicted indications for Afamelanotide with the latest health news. Indications highlighted in orange have recent news coverage.

Drug Information

• Original indication: Prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).
• Evidence level: L5
• Predicted indications (20):
  • X-linked erythropoietic protoporphyria (98.9%)
  • autosomal erythropoietic protoporphyria (98.7%)
  • cutaneous porphyria (98.4%)
  • erythropoietic protoporphyria (97.3%)
  • cyclic hematopoiesis (92.9%)
  • primary hyperoxaluria (91.3%)
  • X-linked severe congenital neutropenia (90.7%)
  • autosomal recessive severe congenital neutropenia due to CXCR2 deficiency (90.1%)
  • cold agglutinin disease (90.1%)
  • proteinuria (89.7%)
  • autosomal recessive severe congenital neutropenia due to JAGN1 deficiency (89.1%)
  • autosomal recessive severe congenital neutropenia due to CSF3R deficiency (89.1%)
  • adult idiopathic neutropenia (88.7%)
  • mixed-type autoimmune hemolytic anemia (88.7%)
  • drug-induced autoimmune hemolytic anemia (88.6%)
  • isolated congenital growth hormone deficiency (88.5%)
  • primary CD59 deficiency (88.5%)
  • progeroid syndrome, Petty type (88.4%)
  • progeria-short stature-pigmented nevi syndrome (88.3%)
  • neonatal autoimmune hemolytic anemia (88.2%)

View full drug report →

Related News (0)

No related news yet. When news mentions this drug, it will be collected and shown here automatically.

Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.